ENZN: Enzon Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ENZN: Enzon Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 11.13
Enterprise Value ($M) 9.18
Book Value ($M) 44.97
Book Value / Share 0.61
Price / Book 0.25
NCAV ($M) 44.97
NCAV / Share 0.61
Price / NCAV 0.25

Profitability (mra)
Return on Invested Capital (ROIC) -0.00
Return on Assets (ROA) -0.00
Return on Equity (ROE) -0.00

Liquidity (mrq)
Quick Ratio 82.17
Current Ratio 82.17

Balance Sheet (mrq) ($M)
Current Assets 45.52
Assets 45.52
Liabilities 0.55
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.03
Operating Income -1.33
Net Income 0.78
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 1.12
Cash from Investing 0.00
Cash from Financing -1.27

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
12-19 13D/A Icahn Carl C 48.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2025-04-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2025-02-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)

Similar Companies
ELVAF – Evolva Holding SA EMMA – Emmaus Life Sciences, Inc.
ENZB – Enzo Biochem, Inc. ERGO – Entia Biosciences, Inc.
ETNI – Entest Group, Inc.


Financial data and stock pages provided by
Fintel.io